Guardant Health, Inc. (GH)
- Business Wire
Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024
PALO ALTO, Calif., October 15, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- Business Wire
GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long
PALO ALTO, Calif., September 18, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the peer-reviewed journal Nature Medicine published results from the SCRUM-Japan GOZILA study confirming that selecting targeted therapy on the basis of Guardant360® CDx liquid biopsy results may significantly extend survival for patients with advanced cancer.
